Impact of belantamab mafodotin‐induced ocular toxicity on outcomes of patients with advanced multiple myeloma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Impact of belantamab mafodotin‐induced ocular toxicity on outcomes of patients with advanced multiple myeloma

Published:2022-06-13 Issue:1 Volume:199 Page:95-99
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Abeykoon Jithma P.¹^ORCID,Vaxman Julia¹^ORCID,Patel Sanjay V.²,Kumar Shaji¹^ORCID,Malave Gabriella C.¹,Young Kimberly S.¹,Ailawadhi Sikander³^ORCID,Larsen Jeremy T.⁴,Dispenzieri Angela¹,Muchtar Eli¹^ORCID,Gonsalves Wilson I.¹^ORCID,Kourelis Taxiarchis¹^ORCID,Leung Nelson¹^ORCID,Warsame Rahma¹,Go Ronald S.¹,Bergsagel Leif¹,Lacy Martha Q.¹,Rajkumar S. Vincent¹,Gertz Morie A.¹,Kapoor Prashant¹

Affiliation:

1. Division of Hematology, Department of Internal Medicine Mayo Clinic Rochester Minnesota USA

2. Department of Ophthalmology Mayo Clinic Rochester Minnesota USA

3. Division of Hematology and Oncology Mayo Clinic Jacksonville Florida USA

4. Division of Hematology Mayo Clinic Scottsdale Arizona USA

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.18298

Reference19 articles.

1. Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads

2. Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody–Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study

3. Novel anti–B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma

4. Ocular Adverse Events Associated with Antibody–Drug Conjugates in Human Clinical Trials

5. Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ocular adverse events associated with antibody-drug conjugates for cancer: evidence and management strategies;The Oncologist;2024-07-24

2. Belantamab mafodotin in triple‐refractory multiple myeloma patients: A retro‐prospective observational study in Italy;eJHaem;2024-04-30

3. Belantamab mafodotin, lenalidomide, and dexamethasone in transplant‐ineligible patients with newly diagnosed multiple myeloma: Analysis of belantamab mafodotin‐associated ocular adverse events and their impact on daily functioning from the part 1 of a phase 1/2 study;American Journal of Hematology;2024-01-25

4. Antibody-Drug Conjugates and Ocular Toxicity;Journal of Ocular Pharmacology and Therapeutics;2023-12-01

5. A safety review of recently approved and emerging drugs for patients with relapsed or refractory multiple myeloma;Expert Opinion on Drug Safety;2023-11-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3